Get access to our best features
Get Started
SubscribeLogin
Get access to our best features
Get Started
Published

Pfizer posts trial win in cancer weight loss (NYSE:PFE)

Summary by The New York Ledger
JHVEPhoto/iStock Editorial by means of Getty Images Pfizer ( NYSE: PFE) revealed Saturday that its speculative treatment ponsegromab targeted at cachexia, a deadly losing condition connected with cancer, reached the main endpoint in a Stage 2 trial. The New York-based pharma giant stated that ponsegromab, a monoclonal antibody, increased body weight after 12 weeks of subcutaneous treatment at all dosages checked, reaching the trial’s primary …
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Pfizer

Pfizer

Cancer

Cancer

New York City

New York City

Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2025 Snapwise Inc
News
For You
Search
BlindspotLocal